First trimester serum neutrophil gelatinase-associated lipocalin in gestational diabetes
Article first published online: 18 AUG 2009
© 2009 The Authors. Journal compilation © 2009 Diabetes UK
Volume 26, Issue 12, pages 1293–1295, December 2009
How to Cite
D’Anna, R., Baviera, G., Corrado, F., Giordano, D., Recupero, S. and Di Benedetto, A. (2009), First trimester serum neutrophil gelatinase-associated lipocalin in gestational diabetes. Diabetic Medicine, 26: 1293–1295. doi: 10.1111/j.1464-5491.2009.02830.x
- Issue published online: 24 NOV 2009
- Article first published online: 18 AUG 2009
- Accepted 8 August 2009
- gestational diabetes;
- neutrophil gelatinase-associated lipocalin
Aims Neutrophil gelatinase-associated lipocalin (NGAL) is highly expressed in damaged epithelia, during inflammation and cardiovascular disease. Soluble NGAL was measured in women who subsequently developed gestational diabetes.
Methods From a cohort of 908 pregnant outpatients who participated in a screening programme for Down’s syndrome at 9–12 weeks of gestation, we considered all 41 women with a singleton pregnancy, who developed gestational diabetes in the previous 12 months, and a control group of 82 normal pregnancies. Circulating NGAL and insulin resistance by homeostasis model assessment ratio (HOMA-IR) were determined in the first trimester.
Results Median serum NGAL concentrations were higher in the gestational diabetes group [51.3 ng/ml (39.8–66.1 ng/ml)] compared with the control group [17.8 ng/ml (15.5–20.9 ng/ml)] (P < 0.001) and positively correlated with HOMA-IR (P < 0.001).
Conclusions In the first trimester, circulating NGAL was significantly increased in women who subsequently developed gestational diabetes compared with the control group.